Medline stock made a blockbuster debut on Wednesday with its IPO listing at $29 per share.
The company raised roughly $6.26 billion and hit the public markets with an implied valuation near $50 billion, making it the year’s biggest listing.
The Northfield, Illinois-based medical-supplies giant, backed by Blackstone, Carlyle, and Hellman & Friedman, upsized the deal to meet robust institutional demand.
Opening trades suggested the stock could gap higher on day one.
But investors need to focus on some critical factors like debt paydown execution, tariff headwinds baked into margins, and whether the company can sustain a premium valuation in a crowded healthcare-distribution market.
Medline stock: Will the IPO materially de-lever?
Medline is carrying roughly $17 billion in debt, a hangover from the 2021 leveraged buyout.
The company plans to use IPO proceeds, primarily from the 179 million shares newly issued, to repay senior secured term loan facilities.
That move is credit-positive and signals discipline to rating agencies.
Fitch praised the deleveraging strategy, noting it should reduce interest expense and improve financial flexibility.
The analysts are closely analysing the math. If Medline allocates $3–$4 billion to debt paydown, it would trim leverage ratios by 0.5–1.0x.
That’s material but not transformative. Free cash flow remains the key.
For the nine months ended September 2025, the company generated roughly $1 billion in net income on $20.6 billion in revenue, with $2.7 billion in adjusted EBITDA and a 13.3% margin.
Those are solid numbers. The investors will next watch whether working capital management stays tight.
The company’s 98% Prime Vendor retention rate means customer relationships are durable, supporting steady cash generation.
But interest coverage and absolute debt levels will remain under scrutiny.
Analysts will be keen to see whether the company can hit a net leverage target of 2.5–3.0x within 18–24 months.
Can growth offset headwinds?
Gross margins sit at a healthy 27.5%, stable year-over-year. But operating margins are the real story.
Medline faces a significant tariff headwind. According to company filings, tariffs could drag earnings before taxes by $325–$375 million in 2025 and $150–$200 million further in 2026.
That’s a material offset to organic growth.
The company sources about one-third of its product portfolio in-house from 33 manufacturing facilities; the rest flows from 500-plus suppliers across 40 countries.
A tariff-exposed import base means Medline must choose between absorbing costs or passing them on to hospitals and health systems.
Most healthcare distributors can only pass through 40–50% of tariff costs; the rest sticks to the P&L.
Competition is also heating up. Cardinal Health, McKesson, and Owens & Minor all vie for the same contracts.
Private-label penetration and customer consolidation continue to squeeze pricing.
The competitive field remains fragmented, which helps scale players like Medline. But margin expansion will be hard-won.
The investors should mark their calendar for the lock-up expiration (typically 180 days post-IPO) and the first earnings report as a public company.
For now, the IPO’s success hinges on execution: clean deleveraging, tariff mitigation, and margin discipline.
The post Medline stock debuts at $29: what investors should watch after IPO appeared first on Invezz